Wishing you all the joys of the season! 
Asia Pacific Infectious Disease Therapeutics Market Forecast to 2030
Asia Pacific Infectious Disease Therapeutics Market Forecast to 2030 – Regional Analysis – by Drug Class (Anti-viral, Anti-Bacterial, Anti-Fungal, and Others), Indication (HIV, Hepatitis, Tuberculosis, Influenza, HPV, and Others), Route Of Administration (Oral, Parenteral, Topical, and Others), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others)
$2,485 – $3,885
- Description
- Toplines
- Reasons for Buying
- Table of Contents
- List of Tables
- LIst of Figures
- List of Companies
- Reviews (0)
Description
Growing Opportunities in Developing Nations Boost Asia Pacific Infectious Disease Therapeutics Market
The growing incidence of infectious diseases is anticipated to increase the sales of infectious disease therapeutics drugs in developing countries. Asia Pacific has become an adaptable and business-friendly hub due to moderately fewer data requirements and stringent regulations. In addition, high investments in health research and life science in emerging countries play a key role in promoting the latest technologies in developing countries, which, in turn, supports the inclination toward infectious disease diagnosis and treatment. For instance, UNAIDS is calling for an investment of US$ 29 billion by 2025 to meet the needs of low- and middle-income countries in the AIDS response. Thus, crucial infectious disease therapeutics product manufacturers in emerging infectious disease therapeutics markets in India and South Korea, are expected to witness lucrative opportunities in the future. This is owing to the high prevalence of infectious diseases such as Hepatitis, HAI, HIV, and influenza; a large population of patients; a rise in disposable income of the population; improving infrastructure of healthcare; and growing medical tourism in these countries.
Asia Pacific Infectious Disease Therapeutics Market Overview
The Asia Pacific infectious disease therapeutics market is sub-segmented into China, India, Japan, South Korea, Australia, and the Rest of Asia Pacific. Asia Pacific is expected to register the fastest CAGR during the forecast period. The market in the region is expected to grow owing to rising global healthcare expenditure, increasing incidence of chronic and infectious diseases, and a growing geriatric population base. The infectious disease such as influenza, hepatitis B, and infectious diarrhea are common in China and typhoid, malaria, jaundice, tuberculosis, and AIDS in India. Influenza, hepatitis B, and infectious diarrhea are the three common infectious diseases in China. As stated by Frontiers Public Health, the winter peak of influenza coincided with the outbreak of COVID-19 in the country in 2021. According to the World Bank Country Director of China 2020, the country is at a high risk of infectious diseases due to its growing population, wildlife abundance, habitat fragmentation, and high livestock production levels. Considering the country’s growing incidence of infectious diseases, the World Bank’s Board of Executive Directors approved a US$ 300 million loan for the Emerging Infectious Diseases Prevention, Preparedness and Response Project. This will help it reduce the risk of zoonotic and other emerging health threats. Thus, the rising incidence of infectious diseases and measures taken to control these diseases are expected to boost the China infectious disease therapeutics market in the coming years.
Asia Pacific Infectious Disease Therapeutics Market Revenue and Forecast to 2030 (US$ Million)
Asia Pacific Infectious Disease Therapeutics Market Segmentation
The Asia Pacific infectious disease therapeutics market is categorized into drug class, indication, route of administration, distribution channel, and country.
Based on drug class, the Asia Pacific infectious disease therapeutics market is segmented into anti-viral, anti-bacterial, anti-fungal, and others. The anti-viral segment held the largest market share in 2022.
In terms of indication, the Asia Pacific infectious disease therapeutics market is segmented into HIV, hepatitis, tuberculosis, influenza, HPV, and others. The HIV held the largest market share in 2022.
Based on route of administration, the Asia Pacific infectious disease therapeutics market is segmented into oral, parenteral, topical, and others. The oral segment held the largest market share in 2022.
In terms of distribution channel, the Asia Pacific infectious disease therapeutics market is segmented into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies held the largest market share in 2022.
By country, the Asia Pacific infectious disease therapeutics market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific infectious disease therapeutics market share in 2022.
AbbVie Inc, Astellas Pharma Inc, Bayer AG, F. Hoffmann-La Roche Ltd, Gilead Sciences Inc, GSK Plc , Merck & Co Inc, Pfizer Inc, and Shionogi & Co Ltd are some of the leading companies operating in the Asia Pacific infectious disease therapeutics market.
Summary Info
| Industry: | |
|---|---|
| Pricing options: | |
| Geographical coverage: | |
| Year of Publication: |
According to the Research Team’ research, the Asia Pacific infectious disease therapeutics market was valued at US$ 25,904.61 million in 2022 and is projected to reach US$ 37,415.07 million by 2030, registering a CAGR of 4.7% from 2022 to 2030. Rising prevalence of infectious disease and increasing focus on funding and R&D in infectious disease therapeutics are among the critical factors attributed to drive the Asia Pacific infectious disease therapeutics market growth.
Research and development (R&D) is a critical part of the business of biopharmaceuticals and pharmaceutical companies. R&D enables them to launch new products for several therapeutic applications with significant medical and commercial potential. Also, leading market players are investing in R&D to develop enhanced technologies and gain more revenue share.
The Indian government has demonstrated previously unseen determination in combating infectious diseases, particularly tuberculosis, by implementing an ambitious national strategy that aims to eradicate the disease by 2025. One of the biggest recipients of grants from the Global Fund is India. The Global Fund has awarded more than US$ 2.36 billion in grants to India for initiatives aimed at combating the three illnesses since 2003 as of November 2020. India has received US$ 500 million from the Global Fund for the 2020–2022 allocation period. Additionally, the National Healthcare Group (NHG), the Agency for Science, Technology and Research (A*STAR), the Lee Kong Chian School of Medicine (LKCMedicine) at Nanyang Technological University, Singapore (NTU Singapore), and the National Centre for Infectious Diseases (NCID) have launched a tripartite program in infectious diseases for new discoveries and treatments (TRIDENT). The collaborative program, which has allocated US$ ~6.65 million in financing, aims to improve knowledge and capacities to address three priority disease areas while also expediting local research in infectious diseases. The primary infectious diseases burden for mortality and morbidity in Singapore was used to identify these disease areas: emerging infectious diseases, respiratory tract infections, and antimicrobial resistance (AMR). Thus, rising focus on R&D and funding in infectious disease therapeutics drive the infectious disease therapeutics market growth.
On the contrary, emergence of anti-infective drugs resistance and associated side effects hamper the growth of the Asia Pacific infectious disease therapeutics market.
Based on drug class, the Asia Pacific infectious disease therapeutics market is segmented into anti-viral, anti-bacterial, anti-fungal, and others. The anti-viral segment held 44.4% market share in 2022, amassing US$ 11,509.82 million. It is projected to garner US$ 16,781.44 million by 2030 to register 4.8% CAGR during 2022–2030.
In terms of indication, the Asia Pacific infectious disease therapeutics market is segmented into HIV, hepatitis, tuberculosis, influenza, HPV, and others . The HIV segment held 35.9% share of Asia Pacific infectious disease therapeutics market in 2022, amassing US$ 9,308.72 million. It is anticipated to garner US$ 13,884.60 million by 2030 to expand at 5.1% CAGR during 2022–2030.
Based on route of administration, the Asia Pacific infectious disease therapeutics market is segmented into oral, parenteral, topical, and others. The oral segment held 55.7% market share in 2022, amassing US$ 14,431.15 million. It is projected to garner US$ 21,172.07 million by 2030 to register 4.9% CAGR during 2022–2030.
In terms of distribution channel, the Asia Pacific infectious disease therapeutics market is segmented into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment held 49.1% share of Asia Pacific infectious disease therapeutics market in 2022, amassing US$ 12,717.11 million. It is anticipated to garner US$ 18,751.24 million by 2030 to expand at 5.0% CAGR during 2022–2030.
Based on country, the Asia Pacific infectious disease therapeutics market is categorized into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. Our regional analysis states that China captured 27.4% share of Asia Pacific infectious disease therapeutics market in 2022. It was assessed at US$ 7,092.19 million in 2022 and is likely to hit US$ 10,577.83 million by 2030, registering a CAGR of 5.1% during 2022–2030.
Key players operating in the Asia Pacific infectious disease therapeutics market are AbbVie Inc, Astellas Pharma Inc, Bayer AG, F. Hoffmann-La Roche Ltd, Gilead Sciences Inc, GSK Plc, Merck & Co Inc, Pfizer Inc, and Shionogi & Co Ltd, among others.
In June 2022, GSK plc invested £1bn over ten years to accelerate research and development (R&D) dedicated to infectious diseases that disproportionately impact lower-income countries. This research will focus on new and disruptive vaccines and medicines to prevent and treat malaria, tuberculosis, HIV (through ViiV Healthcare), neglected tropical diseases (NTDs), and anti-microbial resistance (AMR), which continue to have a devastating toll on the most vulnerable, accounting for more than 60% of the disease burden in many lower-income countries.
o Highlights key business priorities in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific infectious disease therapeutics market, thereby allowing players across the value chain to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the Asia Pacific infectious disease therapeutics market, as well as those hindering it.
o Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.
1. Introduction
1.1 The the Reporting Teams Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Asia Pacific Infectious Disease Therapeutics Market – Key Market Dynamics
4.1 Asia Pacific Infectious Disease Therapeutics Market – Key Market Dynamics
4.2 Market Drivers
4.2.1 Rising Prevalence of Infectious Disease
4.2.2 Increasing Focus on Funding and R&D in Infectious Disease Therapeutics
4.3 Market Restraints
4.3.1 Emergence of Anti-infective Drugs Resistance and Associated Side Effects
4.4 Market Opportunities
4.4.1 Growing Opportunities in Developing Nations
4.4.2 Escalating Threat of Antibiotic Resistance
4.5 Future Trends
4.5.1 Rising Number of Product Approvals and Launches
4.6 Impact of Drivers and Restraints:
5. Infectious Disease Therapeutics Market – Asia Pacific Market Analysis
5.1 Asia Pacific Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030
6. Asia Pacific Infectious Disease Therapeutics Market Analysis – by Drug Class
6.1 Overview
6.2 Anti-Viral
6.2.1 Overview
6.2.2 Anti-viral: Asia Pacific Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
6.3 Anti-bacterial
6.3.1 Overview
6.3.2 Anti-bacterial: Asia Pacific Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
6.4 Anti-fungal
6.4.1 Overview
6.4.2 Anti-fungal: Asia Pacific Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
6.5 Others
6.5.1 Overview
6.5.2 Others: Asia Pacific Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
7. Asia Pacific Infectious Disease Therapeutics Market Analysis – by Indication
7.1 Overview
7.2 HIV
7.2.1 Overview
7.2.2 HIV: Asia Pacific Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
7.3 Hepatitis
7.3.1 Overview
7.3.2 Hepatitis: Asia Pacific Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Tuberculosis
7.4.1 Overview
7.4.2 Tuberculosis: Asia Pacific Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
7.5 Influenza
7.5.1 Overview
7.5.2 Influenza: Asia Pacific Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
7.6 HPV
7.6.1 Overview
7.6.2 HPV: Asia Pacific Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
7.7 Others
7.7.1 Overview
7.7.2 Others: Asia Pacific Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
8. Asia Pacific Infectious Disease Therapeutics Market Analysis – by Route of Administration
8.1 Overview
8.2 Oral
8.2.1 Overview
8.2.2 Oral: Asia Pacific Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
8.3 Parenteral
8.3.1 Overview
8.3.2 Parenteral: Asia Pacific Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Topical
8.4.1 Overview
8.4.2 Topical: Asia Pacific Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
8.5 Others
8.5.1 Overview
8.5.2 Others: Asia Pacific Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
9. Asia Pacific Infectious Disease Therapeutics Market Analysis – by Distribution Channel
9.1 Overview
9.2 Hospital Pharmacies
9.2.1 Overview
9.2.2 Hospital Pharmacies: Asia Pacific Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
9.3 Retail Pharmacies
9.3.1 Overview
9.3.2 Retail Pharmacies: Asia Pacific Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
9.4 Others
9.4.1 Overview
9.4.2 Others: Asia Pacific Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
10. Asia Pacific Infectious Disease Therapeutics Market – Country Analysis
10.1 Asia Pacific Infectious Disease Therapeutics Market Overview
10.1.1 Asia Pacific Infectious Disease Therapeutics Market – Revenue and Forecast Analysis – by Country
10.1.1.1 Asia Pacific Infectious Disease Therapeutics Market – Revenue and Forecast Analysis – by Country
10.1.1.2 China: Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.2.1 Overview
10.1.1.3 China: Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.3.1 China: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.3.2 China: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.3.3 China: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.3.4 China: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
10.1.1.4 Japan: Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.4.1 Overview
10.1.1.5 Japan: Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.5.1 Japan: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.5.2 Japan: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.5.3 Japan: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.5.4 Japan: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
10.1.1.6 India: Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.6.1 Overview
10.1.1.7 India: Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.7.1 India: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.7.2 India: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.7.3 India: Infectious Disease Therapeutics Market Breakdown, by Route Of Administration
10.1.1.7.4 India: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
10.1.1.8 Australia: Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.8.1 Overview
10.1.1.9 Australia: Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.9.1 Australia: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.9.2 Australia: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.9.3 Australia: Infectious Disease Therapeutics Market Breakdown, by Route Of Administration
10.1.1.9.4 Australia: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
10.1.1.10 South Korea: Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.10.1 Overview
10.1.1.11 South Korea: Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.11.1 South Korea: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.11.2 South Korea: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.11.3 South Korea: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.11.4 South Korea: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
10.1.1.12 Rest of Asia Pacific: Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.12.1 Overview
10.1.1.13 Rest of Asia Pacific: Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.13.1 Rest of Asia Pacific: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.13.2 Rest of Asia Pacific: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.13.3 Rest of Asia Pacific: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.13.4 Rest of Asia Pacific: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
11. Infectious Disease Therapeutics Market-Industry Landscape
11.1 Overview
11.2 Growth Strategies in the Infectious Disease Therapeutics Market
11.3 Inorganic Growth Strategies
11.3.1 Overview
11.4 Organic Growth Strategies
11.4.1 Overview
12. Company Profiles
12.1 Pfizer Inc
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Gilead Sciences Inc
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 F. Hoffmann-La Roche Ltd
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Shionogi & Co Ltd
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Bayer AG
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 GSK Plc
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 AbbVie Inc
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Merck & Co Inc
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Astellas Pharma Inc
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
13. Appendix
13.1 About The the Reporting Teams
Table 1. Asia Pacific Infectious Disease Therapeutics Market Segmentation
Table 2. Asia Pacific Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million) – by Drug Class
Table 3. Asia Pacific Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million) – by Indication
Table 4. Asia Pacific Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million) – by Route of Administration
Table 5. Asia Pacific Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million) – by Distribution Channel
Table 6. Asia Pacific Infectious Disease Therapeutics Market – Revenue and Forecast to 2030(US$ Million) – by Country
Table 7. China: Infectious Disease Therapeutics Market – Revenue and Forecast to 2030(US$ Million) – by Drug Class
Table 8. China: Infectious Disease Therapeutics Market – Revenue and Forecast to 2030(US$ Million) – by Indication
Table 9. China: Infectious Disease Therapeutics Market – Revenue and Forecast to 2030(US$ Million) – by Route of Administration
Table 10. China: Infectious Disease Therapeutics Market – Revenue and Forecast to 2030(US$ Million) – by Distribution Channel
Table 11. Japan: Infectious Disease Therapeutics Market – Revenue and Forecast to 2030(US$ Million) – by Drug Class
Table 12. Japan: Infectious Disease Therapeutics Market – Revenue and Forecast to 2030(US$ Million) – by Indication
Table 13. Japan: Infectious Disease Therapeutics Market – Revenue and Forecast to 2030(US$ Million) – by Route of Administration
Table 14. Japan: Infectious Disease Therapeutics Market – Revenue and Forecast to 2030(US$ Million) – by Distribution Channel
Table 15. India: Infectious Disease Therapeutics Market – Revenue and Forecast to 2030(US$ Million) – by Drug Class
Table 16. India: Infectious Disease Therapeutics Market – Revenue and Forecast to 2030(US$ Million) – by Indication
Table 17. India: Infectious Disease Therapeutics Market – Revenue and Forecast to 2030(US$ Million) – by Route Of Administration
Table 18. India: Infectious Disease Therapeutics Market – Revenue and Forecast to 2030(US$ Million) – by Distribution Channel
Table 19. Australia: Infectious Disease Therapeutics Market – Revenue and Forecast to 2030(US$ Million) – by Drug Class
Table 20. Australia: Infectious Disease Therapeutics Market – Revenue and Forecast to 2030(US$ Million) – by Indication
Table 21. Australia: Infectious Disease Therapeutics Market – Revenue and Forecast to 2030(US$ Million) – by Route Of Administration
Table 22. Australia: Infectious Disease Therapeutics Market – Revenue and Forecast to 2030(US$ Million) – by Distribution Channel
Table 23. South Korea: Infectious Disease Therapeutics Market – Revenue and Forecast to 2030(US$ Million) – by Drug Class
Table 24. South Korea: Infectious Disease Therapeutics Market – Revenue and Forecast to 2030(US$ Million) – by Indication
Table 25. South Korea: Infectious Disease Therapeutics Market – Revenue and Forecast to 2030(US$ Million) – by Route of Administration
Table 26. South Korea: Infectious Disease Therapeutics Market – Revenue and Forecast to 2030(US$ Million) – by Distribution Channel
Table 27. Rest of Asia Pacific: Infectious Disease Therapeutics Market – Revenue and Forecast to 2030(US$ Million) – by Drug Class
Table 28. Rest of Asia Pacific: Infectious Disease Therapeutics Market – Revenue and Forecast to 2030(US$ Million) – by Indication
Table 29. Rest of Asia Pacific: Infectious Disease Therapeutics Market – Revenue and Forecast to 2030(US$ Million) – by Route of Administration
Table 30. Rest of Asia Pacific: Infectious Disease Therapeutics Market – Revenue and Forecast to 2030(US$ Million) – by Distribution Channel
Table 31. Recent Inorganic Growth Strategies in the Infectious Disease Therapeutics Market
Table 32. Recent Organic Growth Strategies in the Infectious Disease Therapeutics Market
Figure 1. Asia Pacific Infectious Disease Therapeutics Market Segmentation, by Country
Figure 2. Impact Analysis of Drivers and Restraints
Figure 3. Asia Pacific Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030
Figure 4. Asia Pacific Infectious Disease Therapeutics Market Share (%) – by Drug Class (2022 and 2030)
Figure 5. Anti-viral: Asia Pacific Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 6. Anti-bacterial: Asia Pacific Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 7. Anti-fungal: Asia Pacific Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. Others: Asia Pacific Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. Asia Pacific Infectious Disease Therapeutics Market Share (%) – by Indication (2022 and 2030)
Figure 10. HIV: Asia Pacific Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 11. Hepatitis: Asia Pacific Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12. Tuberculosis: Asia Pacific Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Influenza: Asia Pacific Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 14. HPV: Asia Pacific Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 15. Others: Asia Pacific Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 16. Asia Pacific Infectious Disease Therapeutics Market Share (%) – by Route Of Administration (2022 and 2030)
Figure 17. Oral: Asia Pacific Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 18. Parenteral: Asia Pacific Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 19. Topical: Asia Pacific Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 20. Others: Asia Pacific Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 21. Asia Pacific Infectious Disease Therapeutics Market Share (%) – by Distribution Channel (2022 and 2030)
Figure 22. Hospital Pharmacies: Asia Pacific Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 23. Retail Pharmacies: Asia Pacific Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 24. Others: Asia Pacific Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 25. Asia Pacific Infectious Disease Therapeutics Market, by Key Country – Revenue (2022) (US$ Million)
Figure 26. Asia Pacific Infectious Disease Therapeutics Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 27. China: Infectious Disease Therapeutics Market – Revenue and Forecast to 2030(US$ Million)
Figure 28. Japan: Infectious Disease Therapeutics Market – Revenue and Forecast to 2030(US$ Million)
Figure 29. India: Infectious Disease Therapeutics Market – Revenue and Forecast to 2030(US$ Million)
Figure 30. Australia: Infectious Disease Therapeutics Market – Revenue and Forecast to 2030(US$ Million)
Figure 31. South Korea: Infectious Disease Therapeutics Market – Revenue and Forecast to 2030(US$ Million)
Figure 32. Rest of Asia Pacific: Infectious Disease Therapeutics Market – Revenue and Forecast to 2030(US$ Million)
Figure 33. Growth Strategies in the Infectious Disease Therapeutics Market
The List of Companies – Asia Pacific Infectious Disease Therapeutics Market
1. AbbVie Inc
2. Astellas Pharma Inc
3. Bayer AG
4. F. Hoffmann-La Roche Ltd
5. Gilead Sciences Inc
6. GSK Plc
7. Merck & Co Inc
8. Pfizer Inc
9. Shionogi & Co Ltd
You must be logged in to post a review.
Reviews
There are no reviews yet.